

|                     |  |                  |              |
|---------------------|--|------------------|--------------|
| <b>Policy Name:</b> | <b>Somatuline Depot (lanreotide acetate)</b> | <b>Policy #:</b> | <b>2480P</b> |
|---------------------|--|------------------|--------------|

## Purpose of the Policy

The purpose of this policy is to establish the criteria for coverage of Somatuline Depot.

## Statement of the Policy

Health Alliance Medical Plans and Health Alliance Northwest will approve the use of Somatuline Depot under the specialty medical benefit when the following criteria have been met.

## Criteria

### 1. Coverage Criteria for the Treatment of Acromegaly

- 1.1 Prescribed by an endocrinologist (hormone doctor)
- 1.2 Diagnosis of acromegaly
- 1.3 High Insulin-like Growth Factor (IGF-1) levels for age (lab values are required)
- 1.4 Documented inadequate response to surgery or radiotherapy or clinical reason why the patient has not had surgery or radiotherapy
- 1.5 Documented trial and failure or contraindication to Sandostatin or Sandostatin LAR

### 2. Coverage Criteria for the Treatment of High-Grade Poorly-Differentiated NET

- 2.1 Prescribed by a specialist knowledgeable in the treatment of NETs
- 2.2 Somatuline will be used in conjunction with cancer treatment

### 3. Coverage Criteria for the Treatment of Well-Differentiated (Carcinoid) NET

- 3.1 Prescribed by a specialist knowledgeable in the treatment of NETs
- 3.2 Diagnosis of one of the following: spreading unresectable disease, cancer releasing tumors, significant tumor burden, abnormal lung tumors despite cancer treatment, or lung NET with positive octreotide scan

### 4. Coverage Criteria for the Treatment of Pancreatic NET

- 4.1 Prescribed by a specialist knowledgeable in the treatment of NETs
- 4.2 Diagnosis of one of the following
  - Insulinoma (pancreas tumors)
  - Gastrinoma (intestinal tumors)
  - VIPoma (endocrine tumors)
  - Pituitary adenoma (pituitary tumors)

### 5. Approval Period

- 5.1 Initial: 12 months
- 5.2 Reauthorization: 12 months with documented clinical benefit

## HCPCS Codes

|       |                                     |
|-------|-------------------------------------|
| J1930 | Injection, lanreotide, 1 mg         |
| J1932 | Injection, lanreotide, (cipl), 1 mg |

## References

1. Somatuline Depot (lanreotide) [prescribing information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc; February 2023.
2. Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. *Pituitary*. 2021 Feb;24(1):1-13.
3. Giustina A, Barkan A, Beckers A, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. *J Clin Endocrinol Metab*. 2020 Apr 1;105(4):dgz096.
4. Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Neuroendocrine Tumors. [https://nanets.net/images/2020\\_Guidelines\\_Compendum.pdf](https://nanets.net/images/2020_Guidelines_Compendum.pdf) 2020 Aug;49(7):863-881.

**Created Date:** 04/06/16

**Effective Date:** 04/06/16

**Posted to Website:** 01/01/22

**Revision Date:** 06/05/24

### DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.